Agrotech co EvoGene to raise $10m on TASE

The Compugen spin-off genetically enhances crops. It has raised $11 million to date.

Sources inform ''Globes'' that EvoGene Ltd. will hold an IPO on the Tel Aviv Stock Exchange (TASE). The size and value of the IPO have not yet been set, but the company will reportedly raise $10 million at a value of $30-35 million. Clal Finance Underwriting Ltd. will probably be the underwriter.

EvoGene is a spin-off of Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN). It is a bioinformatics drug discovery and diagnostic kits development company, i.e. it seeks regularity in large quantities of biological information using specialized computer programs. In principle, EvoGene uses the same technology that underpins Compugen’s discovery and know-how, except that it applies the information to develop genetically enhanced plants, whereas Compugen works in the human health field.

According to IVC, EvoGene has raised $11 million to date. The company’s main investors are Leon Recanati’s GlenRock Israel, Kadima High-Tech, Israel-Israel Angels Management Ltd., Igal Ahouvi, Zeev Moses, Coronis Greenberg, Martin Gerstel, and the Office of the Chief Scientist (Compugen was part of Am-Shav Technological Applied Development Center).

EvoGene has several projects for changing plants’ characteristics: developing plants that use half the amount of fertilizers for the same crop yield; drought-resistant and saline-resistant crops; long-fiber and better quality cotton; and plants that grow a human protein suitable for the pharmaceutical industry. Protalix Biotherapeutics Inc. (AMEX:PLX) is a partner in this last project.

Published by Globes [online], Israel business news - www.globes.co.il - on April 16, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018